ReShape Lifesciences Inc (RSLS) - Net Assets
Based on the latest financial reports, ReShape Lifesciences Inc (RSLS) has net assets worth $5.83 Million USD as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($9.03 Million) and total liabilities ($3.20 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check RSLS asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $5.83 Million |
| % of Total Assets | 64.57% |
| Annual Growth Rate | N/A |
| 5-Year Change | -101.75% |
| 10-Year Change | -106.89% |
| Growth Volatility | 627.91 |
ReShape Lifesciences Inc - Net Assets Trend (2003–2024)
This chart illustrates how ReShape Lifesciences Inc's net assets have evolved over time, based on quarterly financial data. Also explore balance sheet size of ReShape Lifesciences Inc for the complete picture of this company's asset base.
Annual Net Assets for ReShape Lifesciences Inc (2003–2024)
The table below shows the annual net assets of ReShape Lifesciences Inc from 2003 to 2024. For live valuation and market cap data, see ReShape Lifesciences Inc market cap and net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $-253.00K | -103.80% |
| 2023-12-31 | $6.66 Million | +82.00% |
| 2022-12-31 | $3.66 Million | -92.05% |
| 2021-12-31 | $46.07 Million | +218.00% |
| 2020-12-31 | $14.49 Million | -39.90% |
| 2019-12-31 | $24.11 Million | -23.87% |
| 2018-12-31 | $31.66 Million | -58.54% |
| 2017-12-31 | $76.37 Million | +2498.40% |
| 2016-12-31 | $2.94 Million | -19.98% |
| 2015-12-31 | $3.67 Million | -44.88% |
| 2014-12-31 | $6.66 Million | -54.60% |
| 2013-12-31 | $14.68 Million | +23.61% |
| 2012-12-31 | $11.88 Million | -40.75% |
| 2011-12-31 | $20.04 Million | -32.54% |
| 2010-12-31 | $29.71 Million | +432.29% |
| 2009-12-31 | $5.58 Million | -51.07% |
| 2008-12-31 | $11.41 Million | -74.81% |
| 2007-12-31 | $45.28 Million | +58.47% |
| 2006-12-31 | $28.57 Million | +1347.10% |
| 2005-12-31 | $1.97 Million | +394.71% |
| 2003-12-31 | $-670.00K | -- |
Equity Component Analysis
This analysis shows how different components contribute to ReShape Lifesciences Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 64020000000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $20.00K | % |
| Other Comprehensive Income | $-104.00K | % |
| Other Components | $642.53 Million | % |
| Total Equity | $-253.00K | 100.00% |
ReShape Lifesciences Inc Competitors by Market Cap
The table below lists competitors of ReShape Lifesciences Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
GlobalData PLC
LSE:DATA
|
$9.36 Million |
|
Rigsave S.P.A.
XETRA:H68
|
$9.36 Million |
|
Vantage Corp
NYSE MKT:VNTG
|
$9.36 Million |
|
Micronet Ltd
TA:MCRNT
|
$9.37 Million |
|
California Nanotechnologies Corp
V:CNO
|
$9.35 Million |
|
Enduro Metals Corp
V:ENDR
|
$9.35 Million |
|
Streamplay Studio Ltd
AU:SP8
|
$9.34 Million |
|
Hengli Industrial Development Group Co Ltd
SHE:000622
|
$9.33 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in ReShape Lifesciences Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 6,663,000 to -253,000, a change of -6,916,000 (-103.8%).
- Net loss of 7,130,000 reduced equity.
- Other comprehensive income decreased equity by 16,000.
- Other factors increased equity by 230,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-7.13 Million | -2818.18% |
| Other Comprehensive Income | $-16.00K | -6.32% |
| Other Changes | $230.00K | +90.91% |
| Total Change | $- | -103.80% |
Book Value vs Market Value Analysis
This analysis compares ReShape Lifesciences Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2003-12-31 | $-12219.59 | $3.92 | x |
| 2005-12-31 | $14716.79 | $3.92 | x |
| 2006-12-31 | $160139.95 | $3.92 | x |
| 2007-12-31 | $53708.36 | $3.92 | x |
| 2008-12-31 | $1964.58 | $3.92 | x |
| 2009-12-31 | $3253.70 | $3.92 | x |
| 2010-12-31 | $10232.18 | $3.92 | x |
| 2011-12-31 | $1924.11 | $3.92 | x |
| 2012-12-31 | $871.03 | $3.92 | x |
| 2013-12-31 | $13.34 | $3.92 | x |
| 2014-12-31 | $867708.33 | $3.92 | x |
| 2015-12-31 | $329.86 | $3.92 | x |
| 2016-12-31 | $60560.48 | $3.92 | x |
| 2017-12-31 | $9930689.21 | $3.92 | x |
| 2018-12-31 | $2494.87 | $3.92 | x |
| 2019-12-31 | $768.25 | $3.92 | x |
| 2020-12-31 | $556.57 | $3.92 | x |
| 2021-12-31 | $294187.13 | $3.92 | x |
| 2022-12-31 | $12508.54 | $3.92 | x |
| 2023-12-31 | $1622.35 | $3.92 | x |
| 2024-12-31 | $-12.27 | $3.92 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently ReShape Lifesciences Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -89.06%
- • Asset Turnover: 1.67x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-303.35%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2003 | 0.00% | 0.00% | 0.00x | 0.00x | $-1.83 Million |
| 2005 | -567.99% | 0.00% | 0.00x | 5.85x | $-11.41 Million |
| 2006 | -61.91% | 0.00% | 0.00x | 1.26x | $-20.55 Million |
| 2007 | -63.11% | 0.00% | 0.00x | 1.30x | $-33.10 Million |
| 2008 | -332.08% | 0.00% | 0.00x | 2.48x | $-39.01 Million |
| 2009 | -572.10% | 0.00% | 0.00x | 2.91x | $-32.49 Million |
| 2010 | -58.39% | 0.00% | 0.00x | 1.30x | $-20.32 Million |
| 2011 | -129.72% | 0.00% | 0.00x | 1.62x | $-28.00 Million |
| 2012 | -197.56% | -7519.23% | 0.01x | 2.20x | $-24.65 Million |
| 2013 | -175.63% | -8276.59% | 0.01x | 1.80x | $-27.25 Million |
| 2014 | -392.09% | 0.00% | 0.00x | 2.16x | $-26.80 Million |
| 2015 | -694.23% | -8732.53% | 0.03x | 3.15x | $-25.87 Million |
| 2016 | -794.86% | -2969.62% | 0.11x | 2.40x | $-23.65 Million |
| 2017 | -44.28% | -2627.34% | 0.01x | 1.16x | $-41.45 Million |
| 2018 | -256.30% | -13375.68% | 0.01x | 1.46x | $-84.32 Million |
| 2019 | -307.84% | -491.80% | 0.38x | 1.65x | $-76.62 Million |
| 2020 | -149.30% | -191.43% | 0.30x | 2.56x | $-23.08 Million |
| 2021 | -139.70% | -455.39% | 0.25x | 1.22x | $-66.37 Million |
| 2022 | -1262.33% | -411.16% | 1.01x | 3.04x | $-46.58 Million |
| 2023 | -170.90% | -131.22% | 0.81x | 1.60x | $-12.05 Million |
| 2024 | 0.00% | -89.06% | 1.67x | 0.00x | $-7.10 Million |
Industry Comparison
This section compares ReShape Lifesciences Inc's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $2,432,799,891
- Average return on equity (ROE) among peers: -74.29%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| ReShape Lifesciences Inc (RSLS) | $5.83 Million | 0.00% | 0.55x | $9.35 Million |
| Abbott Laboratories (ABT) | $24.16 Billion | 9.46% | 0.81x | $155.56 Billion |
| Adagio Medical Holdings, Inc Common Stock (ADGM) | $-13.54K | 0.00% | 0.00x | $21.60 Million |
| Aethlon Medical Inc (AEMD) | $9.29 Million | -84.45% | 0.15x | $2.79 Million |
| Acutus Medical Inc (AFIB) | $105.73 Million | -116.68% | 0.61x | $903.35K |
| Adapthealth Corp (AHCO) | $15.14 Million | -140.98% | 14.05x | $1.39 Billion |
| 20/20 Biolabs, Inc. Common Stock (AIDX) | $2.15 Million | -112.84% | 0.45x | $16.04 Million |
| Allurion Technologies, Inc. (ALUR) | $-70.49 Million | 0.00% | 0.00x | $8.60 Million |
| Autonomix Medical, Inc. Common Stock (AMIX) | $644.00K | -309.01% | 0.34x | $4.22 Million |
| Artivion Inc (AORT) | $89.39 Million | 8.74% | 0.25x | $1.73 Billion |
| Apyx Medical Inc (APYX) | $21.15 Million | 2.82% | 0.30x | $125.55 Million |
About ReShape Lifesciences Inc
As of August 14, 2025, ReShape Lifesciences Inc. was acquired by Vyome Therapeutics Inc., in a reverse merger transaction. ReShape Lifesciences Inc. provides products and services that manage and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company's product portfolio includes Lap-Band System to treat obesity and invasive surgical stapling… Read more